SIBN

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.

Wall Street analysts forecast SIBN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SIBN is 22.60 USD with a low forecast of 20.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

SI-BONE Inc revenue for the last quarter amounts to 48.66M USD, increased 20.61 % YoY.

SI-BONE Inc. EPS for the last quarter amounts to -0.11 USD, decreased -31.25 % YoY.

SI-BONE Inc (SIBN) has 349 emplpoyees as of January 10 2026.

Today SIBN has the market capitalization of 886.92M USD.